查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2021040

标靶α射线疗法的全球市场规模、监管核准、专有技术、治疗应用和临床试验见解（2030年）

Global Targeted Alpha Therapy Market Size, Regulatory Approvals, Proprietary Technologies, Therapeutic Applications & Clinical Trials Insight 2030
出版日期: | 出版商: KuicK Research | 英文 120 Pages | 商品交期: 最快1-2个工作天内

价格

全球标靶α疗法市场规模、监管核准、专有技术、治疗应用和临床试验洞察－2030年报告的主要发现和亮点：

  • 区域及全球标靶α疗法市场展望
  • 当前市场概况和未来成长领域
  • 目前正在进行临床试验的标靶α射线疗法数量：超过30种药物
  • 依公司、适应症和阶段分析标靶α盲法治疗临床试验的见解。
  • 对已通过核准的标靶α放射疗法的剂量和定价的深入了解
  • 针对标靶α疗法专有技术平台进行逐家公司分析
  • 根据癌症类型应用标靶α放射疗法
  • 竞争格局

标靶α射线治疗的必要性及本报告的意义

标靶α放射疗法是一种创新的癌症治疗技术，它利用α发射同位素的高线性能量转移特性，在不伤害正常组织的情况下，特异性靶向癌细胞。与其他治疗方法相比，标靶α放射疗法具有更高的特异性和疗效，并且有可能克服抗药性机制，使其成为治疗转移性和抗药性癌症的理想选择。鑑于其他放射源和传统治疗方法的不足，标靶治疗的开发至关重要，而标靶α放射疗法作为一种未来的癌症治疗技术，正备受关注。

目前，全球标靶α粒子发射疗法市场正经历快速成长，多种α粒子发射材料，例如锕-225、砹-211和铅-212，到2026年将进入不同的临床阶段。此外，一些治疗方案在早期研发阶段就已显示出强大的抗肿瘤活性，并有可能帮助解决与摄护腺癌和肝细胞癌相关的问题。

报告中包含对临床试验的深入分析

临床开发仍是标靶α射线治疗市场扩张的关键驱动力。本说明详细介绍了从I期到III期各个阶段的临床试验，重点关注目标患者群体、给药方法、药物组合和结果。例如，ALPHAMEDIX02进行了一项II期临床试验，研究212Pb-DOTAMTATE治疗胃肠道和胰臟神经内分泌肿瘤的疗效，即使在先前接受过β射线治疗的患者中，也取得了60%的高缓解率。早期使用砹-211的试验也证实了其在治疗復发性甲状腺恶性肿瘤的有效性。

本报告还涵盖了联合治疗，这些疗法透过将标靶α射线疗法与雄激素受体拮抗剂、化疗药物或免疫疗法相结合来增强抗肿瘤效果。本报告提供的资讯可用于评估这些疗法的科学性和商业可行性。

引领标靶α粒子疗法研发的主要企业

标靶α粒子增亮疗法的发展趋势涵盖了製药业的老字型大小企业新兴企业。例如，Actinium Pharmaceuticals、Orano Med、NAYA Therapeutics和Fusion Pharma等公司正在开发前沿治疗方法，而NAYA与中国Alpha Nuclide公司在砹-211生产方面的策略伙伴关係，凸显了国际物流和可扩展生产流程的重要性。

此外，併购活动持续影响竞争格局，例如阿斯特捷利康收购Fusion Pharmaceuticals以及百时美施贵宝收购RayzeBio。这些併购措施旨在取得TAT技术、拓展产品线并确保同位素的稳定供应。

技术平台和战略洞察

本报告深入分析了标靶α射线疗法生产中使用的各项技术，包括相关平台、製程以及该领域的最新创新成果。研究指出了一些关键推动因素，例如利用迴旋加速器生产锕-225以及透过化学方法提取铅-212。报告也涵盖了标靶α射线疗法在治疗诊断学、即时影像和肿瘤学方面的发展趋势。

标靶α粒子疗法的未来前景

标靶α放射治疗产业潜力巨大，众多成功案例为其发展提供了有力支撑。技术的进步以及标靶α放射治疗在肿瘤学以外的应用不断拓展，预示着它将成为未来精准医疗的基石。本报告为相关人员提供了关于新兴机会、竞争格局和技术差异化的宝贵见解，这对于在这个快速发展的治疗领域做出明智的决策至关重要。

目录

第一章：调查方法

第二章：标靶α粒子热疗简介

  • 概述
  • 癌症治疗中α射线与β/γ射线的比较

第三章 标靶α粒子热疗－结构与作用机制

  • 结构
  • 作用机制

第四章：标靶α粒子疗法在癌症治疗的应用

  • 骨髓恶性肿瘤
  • 固态肿瘤

第五章：全球标靶α疗法市场概览

  • 当前市场状况
  • 未来成长路径

第六章：区域标靶α疗法市场洞察

  • 我们
  • 欧洲
  • 中国
  • 日本
  • 澳洲

第七章 全球标靶α热疗临床试验概述

  • 步步
  • 公司
  • 适应症

第八章：依公司、适应症和阶段分類的标靶α热疗临床试验概况

  • 临床前
  • 第一阶段
  • 第一/二期
  • 第二阶段
  • 第二/三期
  • 第三阶段

第九章 按公司、国家和适应症分類的市售标靶α疗法的临床研究结果

第十章：佐菲戈－首个核准的标靶α射线疗法

  • 概述和专利考量
  • 价格和剂量

第十一章 标靶α疗法－公司特有的专有技术平台

第十二章：全球标靶α疗法市场动态

  • 促进者和机会
  • 挑战和限制因素

第十三章 竞争格局

  • Actinium Pharma
  • AdvanCell
  • Ariceum Therapeutics
  • Bayer
  • Fusion Pharma
  • Orano Med
  • Perspective Therapeutics
  • RadioMedix
  • RayzeBio
  • Telix Pharmaceuticals

Global Targeted Alpha Therapy Market Size, Regulatory Approvals, Proprietary Technologies, Therapeutic Applications & Clinical Trials Insight 2030 Report findings & Highlights:

  • Global Targeted Alpha Therapy Market Outlook By Region
  • Current Market Overview & Future Growth Avenues
  • Number Of Targeted Alpha Therapy In Clinical Trials: > 30 Drugs
  • Targeted Alpha Therapy Clinical Trials Insight By Company, Indication & Phase
  • Dosage & Pricing insight On Approved Targeted Alpha Therapy
  • Targeted Alpha Therapy Proprietary Technology Platform Insights By Company
  • Targeted Alpha Therapy Applications By Cancer
  • Competitive Landscape

Need For Targeted Alpha Therapies & Why This Report?

Targeted Alpha Therapies represent an innovative technique in cancer treatment that utilizes the high linear energy transfer characteristic of alpha emitting isotopes to specifically target cancerous cells without damaging normal tissue. In contrast to other treatment modalities, Targeted Alpha Therapies provide specificity, efficacy, and the potential to circumvent resistance pathways, thus making them ideal for the treatment of metastatic and drug-resistant cancers. The shortcomings of other radiation emitters and traditional treatments have rendered the development of targeted therapies critical, placing Targeted Alpha Therapies in the spotlight for future cancer therapy techniques.

The global market or targeted alpha therapies is currently experiencing rapid growth due to the advancement of several alpha emitters, such as Actinium-225, Astatine-211, and Lead-212, through various clinical stages in 2026. In addition to this, there are already several therapeutic solutions that showed strong anti-tumor activity in the initial stages of development and can help in dealing with problems related to prostate cancer and hepatocellular carcinoma.

Clinical Trials Insight Included In Report

Clinical development continues to be an important factor behind the expansion of the Targeted Alpha Therapies market. In this report, we discuss various trials at different phases, from Phase I to Phase III, focusing on demographics, dosing regimens, drug combinations, and results. As an example, ALPHAMEDIX02 conducted a Phase II trial for the treatment of gastroenteropancreatic neuroendocrine tumors with 212Pb-DOTAMTATE, which yielded response rates as high as 60% even for patients that had been administered beta-emitting agents previously. Initial trials with Astatine-211 have also proved effective in treating recurrent thyroid malignancies.

Combination therapies are also covered in this report where Targeted Alpha Therapies have been combined with androgen receptor antagonists, chemotherapeutic agents, or immunotherapy to boost antitumor efficacy. With the help of the information provided in this report, it is possible to make an evaluation regarding both scientific and business viability.

Major Companies Driving Targeted Alpha Therapy R&D

The development landscape of targeted alpha therapies comprises of both mature players in the pharmaceutical industry and emerging players. Examples include companies like Actinium Pharmaceuticals, Orano Med, NAYA Therapeutics, and Fusion Pharma that are developing cutting-edge treatments, whereas strategic partnerships, like NAYA's alliance with Alpha Nuclide in China to produce Astatine-211, emphasize the significance of international logistics and scalable manufacturing processes.

There are also merger and acquisition activities that continue to shape the competition environment as seen by the recent acquisition of Fusion Pharmaceuticals by AstraZeneca and the acquisition of RayzeBio by Bristol Myers Squibb. Such mergers and acquisitions represent strategies geared towards gaining access to TAT technology, expanding the pipeline, and ensuring consistent access to isotopes.

Technology Platforms & Strategic Insights Offered

This report offers an insightful analysis of the technologies used in Targeted Alpha Therapies manufacturing, including the platform and processes involved, and the latest innovations in this domain. The study identifies some critical enabling factors such as the process of generating Actinium-225 from a cyclotron and the extraction of Lead-212 through chemistry. The report also captures the trends within the Targeted Alpha Therapy theranostics, real-time imaging, and oncology domains.

Future Outlook For Targeted Alpha Therapy

There is a lot of potential in the targeted alpha therapy industry, and that has been fueled by several successes in the area. As a result of advancements in technology and the broadening scope of Targeted Alpha Therapy applications outside of oncology, it is set to be one of the pillars of precision medicine in the future. By utilizing this report, stakeholders can obtain valuable insights about new opportunities, competitive position, and technology differentiators that are essential for making an informed decision in the ever-changing therapeutic field.

Table of Contents

1. Research Methodology

2. Introduction To Targeted Alpha Therapy

  • 2.1 Overview
  • 2.2 Alpha Radiation vs. Beta & Gamma Radiation In Cancer Therapy

3. Targeted Alpha Therapy - Structure & Mechanism Of Action

  • 3.1 Structure
  • 3.2 Mechanism Of Action

4. Targeted Alpha Therapy Applications By Cancer

  • 4.1 Hematological Malignancies
  • 4.2 Solid Tumors

5. Global Targeted Alpha Therapy Market Insight

  • 5.1 Current Market Scenario
  • 5.2 Future Growth Avenues

6. Targeted Alpha Therapy Market Insight By Region

  • 6.1 US
  • 6.2 Europe
  • 6.3 China
  • 6.4 Japan
  • 6.5 Australia

7. Global Targeted Alpha Therapy Clinical Trials Overview

  • 7.1 By Phase
  • 7.2 By Company
  • 7.3 By Indication

8. Targeted Alpha Therapy Clinical Trials Insight By Company, Indication & Phase

  • 8.1 Preclinical
  • 8.2 Phase I
  • 8.3 Phase I/II
  • 8.4 Phase II
  • 8.5 Phase II/III
  • 8.6 Phase III

9. Marketed Targeted Alpha Therapy Clinical Insight By Company, Country & Indication

10. Xofigo - 1st Approved Targeted Alpha Therapy

  • 10.1 Overview & Patent Insight
  • 10.2 Pricing & Dosing

11. Targeted Alpha Therapy - Proprietary Technology Platform By Company

12. Global Targeted Alpha Therapy Market Dynamics

  • 12.1 Drivers & Opportunities
  • 12.2 Challenges & Restraints

13. Competitive Landscape

  • 13.1 Actinium Pharma
  • 13.2 AdvanCell
  • 13.3 Ariceum Therapeutics
  • 13.4 Bayer
  • 13.5 Fusion Pharma
  • 13.6 Orano Med
  • 13.7 Perspective Therapeutics
  • 13.8 RadioMedix
  • 13.9 RayzeBio
  • 13.10 Telix Pharmaceuticals

List of Figures

  • Figure 3-1: Targeted Alpha Therapy - Structure
  • Figure 3-2: Targeted Alpha Therapy - Mechanism Of Action
  • Figure 4-1: LIN-AC225-AML02 Phase 1/2 (NCT03867682) Study - Initiation & Completion Year
  • Figure 4-2: RG1121028 Phase 1 (NCT04579523) Study - Initiation & Completion Year
  • Figure 4-3: 225Ac-DOTA-daratumumab Phase 1 (NCT05363111) Study - Initiation & Completion Year
  • Figure 4-4: PAnTHA Phase 1 (NCT06217822) Study - Initiation & Completion Year
  • Figure 4-5: 2022-502623-22-00 Phase 1 (NCT06052306) Study - Initiation & Completion Year
  • Figure 4-6: TheraPb Phase I/II (NCT05720130) Study - Initiation & Completion Year
  • Figure 4-7: VMT-a-NET-T101 Phase I/II (NCT05636618) Study - Initiation & Completion Year
  • Figure 4-8: ALPHAMEDIX02 Phase II (NCT05153772) Study - Initiation & Completion Year
  • Figure 5-1: Factors Influencing Future Market of Targeted Alpha Therapies
  • Figure 5-2: Global - Targeted Alpha Therapy Market Opportunity (US$ Million), 2026 & 2030
  • Figure 7-1: Global - - Number Of Targeted Alpha Therapy Clinical Pipeline By Phase, 2026
  • Figure 7-2: Global - - Number Of Targeted Alpha Therapy Clinical Pipeline By Company, 2026
  • Figure 7-3: Global - - Number Of Targeted Alpha Therapy Clinical Pipeline By Indication, 2026
  • Figure 11-1: Fusion Pharma - Fast-Clear(TM) Linker Technology
  • Figure 11-2: AdvanCell - Proprietary 212Pb Production Technology
  • Figure 11-3: Cellectar Biosciences - Phospholipid Ether (PLE) Platform Technology
  • Figure 11-4: Perspective Therapeutics - Proprietary Technology & Pb-212 Isotope Generator VMT-a-NET
  • Figure 12 1: Global Targeted Alpha Therapy Market - Drivers & Opportunities
  • Figure 12 2: Global Targeted Alpha Therapy Market - Challenges & Restraints

List of Tables

  • Table 2-1: Alpha Radiation vs. Beta & Gamma Radiation In Cancer Therapy
  • Table 8-1: Targeted Alpha Therapies In Preclinical Stage, 2026
  • Table 8-2: Targeted Alpha Therapies In Phase I, 2026
  • Table 8-3: Targeted Alpha Therapies In Phase I/II, 2026
  • Table 8-4: Targeted Alpha Therapies In Phase II, 2026
  • Table 8-5: Targeted Alpha Therapies In Phase II/III, 2026
  • Table 8-6: Targeted Alpha Therapies In Phase III, 2026
  • Table 9-1: Marketed Targeted Alpha Therapies, 2026
  • Table 10-1: Xofigo - Decay Correction Factor